Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Efficacy and Safety of Activated Recombinant Human Factor VII in Treatment of Bleeding in Patients Following Hematopoietic Stem Cell Transplantation

This study has been terminated.
(Trial enrollment was prematurely terminated due to excessively slow patient recruitment)
Sponsor:
Information provided by:
Novo Nordisk A/S
ClinicalTrials.gov Identifier:
NCT01564563
First received: March 23, 2012
Last updated: December 10, 2012
Last verified: December 2012
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: October 2003
  Primary Completion Date: October 2003 (Final data collection date for primary outcome measure)